Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. World most cancers statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J Clin. 2018;49:509.
Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric most cancers: a brand new paradigm. Clin Most cancers Res. 2011;17:2693–701.
Bass AJ, Reynolds SM, Laird PW, Curtis C, Shen H, Weisenberger DJ, et al. Complete molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular evaluation of gastric most cancers identifies subtypes related to distinct medical outcomes. Nat Med. 2015;21:449–56.
Totoki Y, Saito-Adachi M, Shiraishi Y, Komura D, Nakamura H, Suzuki A, et al. Multiancestry genomic and transcriptomic evaluation of gastric most cancers. Nat Genet. 2023;1–14, https://doi.org/10.1038/s41588-023-01333-x.
Sundar R, Kumarakulasinghe NB, Chan YH, Yoshida Okay, Yoshikawa T, Miyagi Y, et al. Machine-learning mannequin derived gene signature predictive of paclitaxel survival profit in gastric most cancers: outcomes from the randomised section III SAMIT trial. Intestine. 2022;71:676–85.
Lei Z, Tan IB, Das Okay, Deng N, Zouridis H, Pattison S, et al. Identification of Molecular Subtypes of Gastric Most cancers With Totally different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil. Gastroenterology. 2013;145:554–65.
McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Previous, Current, and the Future. Cell. 2017;168:613–28.
Oh BY, Shin H-T, Yun JW, Kim Okay-T, Kim J, Bae JS, et al. Intratumor heterogeneity inferred from focused deep sequencing as a prognostic indicator. Sci Rep. 2019;9:4542–8.
Gao S, Tibiche C, Zou J, Zaman N, Trifiro M, et al. Identification and Development of Combinatory Most cancers Hallmark-Primarily based Gene Signature Units to Predict Recurrence and Chemotherapy Profit in Stage II Colorectal Most cancers. JAMA Oncol. 2016;2:37–45.
Kim T-H, Kim I-H, Kang SJ, Choi M, Kim B-H, Eom BW, et al. Korean Apply Tips for Gastric Most cancers 2022: An Proof-based, Multidisciplinary Strategy. J Gastric Most cancers. 2023;23:3–106.
Edge S, Compton C. The American Joint Committee on Most cancers: the seventh Version of the AJCC Most cancers Staging Guide and the Way forward for TNM. Ann Surg Oncol. 2010;17:1471–4.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Version AJCC Most cancers Staging Guide: Persevering with to construct a bridge from a population-based to a extra “personalised” method to most cancers staging. CA Most cancers J Clin. 2017;67:93–99.
Japanese Gastric Most cancers A. Japanese classification of gastric carcinoma: third English version. Gastric Most cancers. 2011;14:101–12.
Oh S-Y, Lee Okay-G, Suh Y-S, Kim MA, Kong S-H, Lee H-J, et al. Lymph Node Metastasis in Mucosal Gastric Most cancers: Reappraisal of Expanded Indication of Endoscopic Submucosal Dissection. Ann Surg. 2017;265:137–42.
Lê Cao Okay-A, Boitard S, Besse P. Sparse PLS discriminant evaluation: biologically related characteristic choice and graphical shows for multiclass issues. BMC Bioinformatics. 2011;12:253–217.
Shivanna S, Harrold I, Shashar M, Meyer R, Kiang C, Francis J, et al. The c-Cbl ubiquitin ligase regulates nuclear β-catenin and angiogenesis by its tyrosine phosphorylation mediated by the Wnt signaling pathway. J. Biol. Chem. 2015;290:12537–46.
Lyle CL, Belghasem M, Chitalia VC, Belghasem M, Chitalia VC. c-Cbl: An Essential Regulator and a Goal in Angiogenesis and Tumorigenesis. Cells. 2019;8:498.
Kakugawa S, Langton PF, Zebisch M, Howell S, Chang TH, Liu Y, et al. Notum deacylates Wnt proteins to suppress signalling exercise. Nature. 2015;519:187–92.
Cao C, Vasilatos SN, Bhargava R, Nice JL, Oesterreich S, Davidson NE, et al. Practical interplay of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast most cancers development. Oncogene. 2017;36:133–45.
Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Chilly Spring Harb Perspect Biol. 2014;6:a018713–a018713.
Wang Okay, Kan J, Yuen ST, Shi ST, Chu KM, Regulation S, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric most cancers. Nat. Genet. 2011;43:1219–23.
Kim JW, Im S-A, Kim MA, Cho HJ, Lee DW, Lee Okay-H, et al. Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric most cancers as prognostic marker. Int J Most cancers. 2014;134:72–80.
Suh YS, Yang HK. Screening and Early Detection of Gastric Most cancers: East Versus West. Surg Clin North Am. 2015;95:1053–66.
Japanese Gastric Most cancers Affiliation. Japanese Gastric Most cancers Therapy Tips 2021 (sixth version). Gastric Most cancers. 2022;1–25. https://doi.org/10.1007/s10120-022-01331-8.
Cheong J-H, Yang H-Okay, Kim H, Kim WH, Kim Y-W, Kook M-C, et al. Predictive check for chemotherapy response in resectable gastric most cancers: a multi-cohort, retrospective evaluation. Lancet Oncol. 2018;19:629–38.
Schizas D, Mastoraki A, Naar L, Tsilimigras DI, Katsaros I, Fragkiadaki V, et al. Histone Deacetylases (HDACs) in Gastric Most cancers: An Replace of their Rising Prognostic and Therapeutic Position. Curr Med Chem. 2020;27:6099–6111.
Weichert W, Röske A, Gekeler V, Beckers T, Ebert MPA, Pross M, et al. Affiliation of patterns of sophistication I histone deacetylase expression with affected person prognosis in gastric most cancers: a retrospective evaluation. Lancet Oncol. 2008;9:139–48.
Hontecillas-Prieto L, Flores-Campos R, Silver A, Álava E, Hajji N, García-Domínguez DJ. Synergistic Enhancement of Most cancers Remedy Utilizing HDAC Inhibitors: Alternative for Scientific Trials. Entrance Genet. 2020;11:578011.
Jiang Z, Li W, Hu X, Zhang Q, Solar T, Cui S, et al. Tucidinostat plus exemestane for postmenopausal sufferers with superior, hormone receptor-positive breast most cancers (ACE): a randomised, double-blind, placebo-controlled, section 3 trial. Lancet Oncol. 2019;20:806–15.
Okuwaki M, Matsumoto Okay, Tsujimoto M, Nagata Okay. Operate of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett. 2001;506:272–6.
Eitoku M, Sato L, Senda T, Horikoshi M. Histone chaperones: 30 years from isolation to elucidation of the mechanisms of nucleosome meeting and disassembly. Cell Mol Life Sci. 2008;65:414–44.
Emmott E, Hiscox JA. Nucleolar concentrating on: the hub of the matter. Embo Rep. 2009;10:231–8.
Nozawa Y, Belzen NV, Made ACJVD, Dinjens WNM, Bosman FT. Expression of nucleophosmin/b23 in regular and neoplastic colorectal mucosa. J Pathol. 1996;178:48–52.
Yun JP, Miao J, Chen GG, Tian QH, Zhang CQ, Xiang J, et al. Elevated expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Most cancers. 2007;96:477–84.
Zhu Y, Shi M, Chen H, Gu J, Zhang J, Shen B, et al. NPM1 prompts metabolic modifications by inhibiting FBP1 whereas selling the tumorigenicity of pancreatic most cancers cells. Oncotarget. 2015;6:21443–51.
Olausson KH, Elsir T, Goudarzi KM, Nistér M, Lindström MS. NPM1 histone chaperone is upregulated in glioblastoma to advertise cell survival and keep nucleolar form. Sci Rep. 2015;5:16495.
Matteo AD, Franceschini M, Chiarella S, Rocchio S, Travaglini-Allocatelli C, Federici L, et al. Molecules that focus on nucleophosmin for most cancers remedy: an replace. Oncotarget. 2016;7:44821–40.
Itahana Okay, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, et al. Tumor Suppressor ARF Degrades B23, a Nucleolar Protein Concerned in Ribosome Biogenesis and Cell Proliferation. Mol Cell. 2003;12:1151–64.
Zhang Y. The ARF-B23 Connection: Implications for Progress Management and Most cancers Therapy. Cell Cycle. 2004;3:257–60.
Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its operate. Mol Cell Biol. 2005;25:1258–71.
Lindström MS. NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Transforming. Biochem Res Int. 2011;2011:195209.
Colombo E, Alcalay M, Pelicci PG. Nucleophosmin and its complicated community: a potential therapeutic goal in hematological illnesses. Oncogene. 2011;30:2595–609.
Shi L, Magee P, Fassan M, Sahoo S, Leong HS, Lee D, et al. A KRAS-responsive lengthy non-coding RNA controls microRNA processing. Nat Commun. 2021;12:2038.
Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An built-in genomics method identifies drivers of proliferation in luminal-subtype human breast most cancers. Nat Genet. 2014;46:1051–9.
Wang S, Hao Q, Li J, Chen Y, Lu H, Wu X, et al. Ubiquitin ligase DTX3 empowers mutant p53 to advertise ovarian most cancers growth. Genes Dis. 2020;9:705–16.
Zhang S, O’Regan R, Xu W. The rising function of mediator complicated subunit 12 in tumorigenesis and response to chemotherapeutics. Most cancers. 2020;126:939–48.
Huang S, Hölzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, et al. MED12 Controls the Response to A number of Most cancers Medication by Regulation of TGF-β Receptor Signaling. Cell. 2012;151:937–50.
Rosell R. Mediating Resistance in Oncogene-Pushed Cancers. New Engl J Med. 2013;368:1551–2.
Okines AFC, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, et al. Epirubicin, Oxaliplatin, and Capecitabine With or With out Panitumumab for Superior Esophagogastric Most cancers: Dose-Discovering Examine for the Potential Multicenter, Randomized, Section II/III REAL-3 Trial. J Clin Oncol. 2010;28:3945–50.
Lordick F, Kang Y-Okay, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or with out cetuximab for sufferers with beforehand untreated superior gastric most cancers (EXPAND): a randomised, open-label section 3 trial. Lancet Oncol. 2013;14:490–9.
Sugiura R, Sio SO, Shuntoh H, Kuno T. Molecular genetic evaluation of the calcineurin signaling pathways. Cell Mol Life Sci Cmls. 2001;58:278–88.
Peuker Okay, Muff S, Wang J, Künzel S, Bosse E, Zeissig Y, et al. Epithelial calcineurin controls microbiota-dependent intestinal tumor growth. Nat Med. 2016;22:506–15.
Solar Z, Xia W, Lyu Y, Tune Y, Wang M, Zhang R, et al. Immune-related gene expression signatures in colorectal most cancers. Oncol Lett. 2021;22:543.
Veldman-Jones MH, Brant R, Rooney C, Geh C, Emery H, Harbron CG, et al. Evaluating Robustness and Sensitivity of the NanoString Applied sciences nCounter Platform to Allow Multiplexed Gene Expression Evaluation of Scientific Samples. Most cancers Res. 2015;75:2587–93.
Waggott D, Chu Okay, Yin S, Wouters BG, Liu F-F, Boutros PC. NanoStringNorm: an extensible R bundle for the pre-processing of NanoString mRNA and miRNA knowledge. Bioinformatics. 2012;28:1546–8.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq knowledge with DESeq2. Genome Biol. 2014;15:550.
Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Strategies. 2014;11:783–4.
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast common RNA-seq aligner. Bioinformatics. 2013;29:15–21.
Li B, Dewey CN. RSEM: correct transcript quantification from RNA-Seq knowledge with or and not using a reference genome. BMC Bioinformatics. 2011;12:323.
Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, et al. Ensembl 2018. Nucleic Acids Res. 2018;46:D754–D761.
Li H. Aligning sequence reads, clone sequences and meeting contigs with BWA-MEM. arXiv. 2013. http://adsabs.harvard.edu/abs/2013arXiv1303.3997L.
Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ knowledge to excessive confidence variant calls: the Genome Evaluation Toolkit finest practices pipeline. Curr Protoc Bioinformatics. 2013;43:11.10.11–33.
Cibulskis Okay, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Delicate detection of somatic level mutations in impure and heterogeneous most cancers samples. Nat Biotechnol. 2013;31:213–9.
Wang Okay, Li M, Hakonarson H. ANNOVAR: Practical annotation of genetic variants from high-throughput sequencing knowledge. Nucleic Acids Res. 2010;38:e164.
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. Variation throughout 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance throughout human protein-coding genes. bioRxiv. 2019;49:531210.
Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP. Maftools: environment friendly and complete evaluation of somatic variants in most cancers. Genome Res. 2018;28:1747–56.
Jeong YS, Eun Y-G, Lee SH, Kang S-H, Yim SY, Kim EH, et al. Clinically conserved genomic subtypes of gastric adenocarcinoma. Mol Most cancers. 2023;22:147.
Jun Y, Suh Y-S, Park S, Lee J, Kim J-I, Lee S, et al. Complete Evaluation of Various Splicing in Gastric Most cancers Identifies Epithelial–Mesenchymal Transition Subtypes Related to Survival. Most cancers Res. 2022;82:543–55.
Sohn BH, Hwang J-E, Jang H-J, Lee H-S, Oh SC, Shim J-J, et al. Scientific Significance of 4 Molecular Subtypes of Gastric Most cancers Recognized by The Most cancers Genome Atlas Undertaking. Clin Most cancers Res. 2017;23:4441–9.
Broad Institute TCGA Genome Knowledge Evaluation Heart. Firehose stddata__2016_01_28 run. Broad Institute of MIT and Harvard; 2016. https://doi.org/10.7908/C11G0KM9.
Goldman M, Craft B, Brooks AN, Zhu J, Haussler D. The UCSC Xena Platform for most cancers genomics knowledge visualization and interpretation. bioRxiv. 2018;326470, https://doi.org/10.1101/326470.
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Sorts of Most cancers. Cell. 2018;173:291–304.e296.
Liu H, Bebu I, Li X. Microarray probes and probe units. Entrance Biosci. 2010;2:325–38.
Mounir M, Lucchetta M, Silva TC, Olsen C, Bontempi G, Chen X, et al. New functionalities within the TCGAbiolinks bundle for the examine and integration of most cancers knowledge from GDC and GTEx. PLoS Comput Biol. 2019;15:e1006701.
